Bristol-Myers Squibb, playing catch-up in hepatitis C, picked up FDA approval for a virus-blocking agent to be used in tandem with Sovaldi, Gilead Sciences' blockbuster success.
Late last year shares of Nymox were put into the shredder after the biotech said that both of its late-stage studies for their lead drug for enlarged prostates had flopped. But the biotech rebounded today after the company claimed that an extension of those studies had produced positive results.
In a conversation with Forbes' Matthew Herper, Allergan CEO Brent Saunders happily spotlighted his bolt-on buyouts with Kythera, Naurex, Furiex and Rhythm. Compare that to recent remarks from Eli Lilly's John Lechleiter, who has always insisted on backing the pipeline he has while adding an occasional pact, or Severin Schwan at Roche. Both see this current market as overpriced.
Aegerion Pharmaceuticals CEO Marc Beer has stepped down from his post after reaching a tenuous cease-fire with activist investors, leaving behind a company with an uncertain future.
Eli Lilly says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed.
The big news in biopharma this weekend is the unconfirmed report that Allergan is looking to sell its generics business to Teva. But Allergan execs didn't let the headlines distract them from another goal of CEO Brent Saunders': building the pipeline.
Four years ago, Pankaj Mohan set out to build an independent biosimilars developer. Today, his company, Oncobiologics, is taking the next big step into late-stage work after raising $31 million from some prominent investors willing to back him at a critical point.
Novartis won accelerated approval for a promising oncology drug, gearing up to launch a new treatment for an advanced form of the most common type of skin cancer.
Sanofi and Regeneron won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped short of giving the treatment the wide label its makers wanted.
Texas biotech Neos Therapeutics cleared $72 million in an IPO, raising cash to develop some reformulated takes on existing drugs for ADHD.
Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make good on blockbuster sales predictions.
Biogen ended a bad week with a blast of bitter news that took another big bite out of its share price. Revenue was off target, with its big growth engine Tecfidera missing its marks in the MS market by a wide berth--creating the kind of nasty surprise that Wall Street analysts hate. And following up on a flop for its top Alzheimer's programs, the company had more failures to report for its R&D group--setting the stage for a more aggressive approach to controlling costs while plotting its next steps in an increasingly expensive M&A game.
Avalanche Biotechnologies' co-founder and CEO is stepping down from the top spot, a month removed from posting mixed clinical results that tanked the company's share value.
Despite its lead drug's failure in a late-stage trial last year, Sunesis Pharmaceuticals held on to hope that it could convince the FDA to give the leukemia treatment a shot at approval. But its argument apparently fell on deaf ears, as the agency asked to see more clinical data before evaluating the therapy.
Roche is terminating its collaboration with Molecular Partners, nixing an oncology partnership worth up to $1 billion as it reshuffles its pipeline.
In this week's EuroBiotech Report, Ablynx expanded its immuno-oncology pact with Merck. If everything comes off, Ablynx will find itself €4 billion richer. The snag? Almost all of the money is tied to milestones, with Merck handing over just €13 million upfront. And more.
Biotech's ongoing boom has inflated valuations for upstart drugmakers, and Eli Lilly CEO John Lechleiter said his company is wary of getting involved in any high-dollar bidding wars to bring in new treatments.
Shares of Inotek Pharmaceuticals soared 65% Thursday morning, after the Lexington, MA-based biotech said that it had completed an end-of-Phase II meeting with the FDA and set up a Phase III strategy for its glaucoma drug trabodenoson.
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including new data on some closely watched treatments for Alzheimer's disease, the latest on a new group of would-be-blockbuster cholesterol drugs and an ad campaign for contraceptives that targets Millennials.